Fu Haitao, Hu Die, Chen Jinli, Wang Qizun, Zhang Yingze, Qi Chao, Yu Tengbo
Department of Sports Medicine, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.
State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Qingdao Eye Hospital, Shandong Eye Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Qingdao, China.
Front Neurosci. 2022 Feb 17;16:800513. doi: 10.3389/fnins.2022.800513. eCollection 2022.
Spinal cord injury (SCI) can result in sensorimotor impairments or disability. Studies of the cellular response to SCI have increased our understanding of nerve regenerative failure following spinal cord trauma. Biological, engineering and rehabilitation strategies for repairing the injured spinal cord have shown impressive results in SCI models of both rodents and non-human primates. Cell transplantation, in particular, is becoming a highly promising approach due to the cells' capacity to provide multiple benefits at the molecular, cellular, and circuit levels. While various cell types have been investigated, we focus on the use of Schwann cells (SCs) to promote SCI repair in this review. Transplantation of SCs promotes functional recovery in animal models and is safe for use in humans with subacute SCI. The rationales for the therapeutic use of SCs for SCI include enhancement of axon regeneration, remyelination of newborn or sparing axons, regulation of the inflammatory response, and maintenance of the survival of damaged tissue. However, little is known about the molecular mechanisms by which transplanted SCs exert a reparative effect on SCI. Moreover, SC-based therapeutic strategies face considerable challenges in preclinical studies. These issues must be clarified to make SC transplantation a feasible clinical option. In this review, we summarize the recent advances in SC transplantation for SCI, and highlight proposed mechanisms and challenges of SC-mediated therapy. The sparse information available on SC clinical application in patients with SCI is also discussed.
脊髓损伤(SCI)可导致感觉运动障碍或残疾。对脊髓损伤细胞反应的研究增进了我们对脊髓创伤后神经再生失败的理解。在啮齿动物和非人类灵长类动物的脊髓损伤模型中,用于修复受损脊髓的生物学、工程学和康复策略已取得了令人瞩目的成果。特别是细胞移植,由于细胞能够在分子、细胞和回路水平上提供多种益处,正成为一种非常有前景的方法。虽然已经研究了各种细胞类型,但在本综述中,我们重点关注使用雪旺细胞(SCs)来促进脊髓损伤的修复。雪旺细胞移植可促进动物模型的功能恢复,并且对亚急性脊髓损伤的人类患者使用是安全的。将雪旺细胞用于脊髓损伤治疗的基本原理包括增强轴突再生、新生轴突或保留轴突的髓鞘再生、调节炎症反应以及维持受损组织的存活。然而,关于移植的雪旺细胞对脊髓损伤发挥修复作用的分子机制知之甚少。此外,基于雪旺细胞的治疗策略在临床前研究中面临相当大的挑战。必须澄清这些问题,以使雪旺细胞移植成为一种可行的临床选择。在本综述中,我们总结了雪旺细胞移植治疗脊髓损伤的最新进展,并强调了雪旺细胞介导治疗的潜在机制和挑战。还讨论了关于雪旺细胞在脊髓损伤患者临床应用的稀少可用信息。